The actin filament-associated protein of 110 kDa (AFAP-110) was ®rst identi®ed as an SH3/SH2 binding partner for the nonreceptor tyrosine kinase, Src. Subsequent data have demonstrated that AFAP-110 can interact with other Src family members. AFAP-110 contains additional protein binding modules including two pleckstrin homology domains, a leucine zipper motif and a target sequence for serine/threonine phosphorylation. AFAP-110 interacts with actin ®laments directly via a carboxy terminal actin-binding domain. Thus AFAP-110 may function as an adaptor protein by linking Src family members and/or other signaling proteins to actin ®laments. AFAP-110 also has an intrinsic capability to alter actin ®lament integrity that can be revealed upon conformational changes associated with phosphorylation or mutagenesis. Recent data has indicated that AFAP-110 may also serve to activate cSrc in response to this conformational change as well. Thus, AFAP-110 may function in several ways by (1) acting as an adaptor protein that links signaling molecules to actin ®laments, (2) serving as a platform for the construction of larger signaling complexes, (3) serving as an activator of Src family kinases in response to cellular signals that alter its conformation and (4) directly eecting actin ®lament organization as an actin ®lament cross-linking protein.
Here, we will review the structure and function of AFAP-110 as well as potential binding partners and eectors of AFAP-110's ability to alter actin ®lament integrity. Oncogene (2001) 20, 6435 ± 6447.
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Early Studies of AFAP-110
The nonreceptor tyrosine kinase, Src, is a well-studied enzyme that has served as a model system for cellular studies on transformation (Brown and Cooper, 1996) . Although much is known of Src, the precise mechanisms by which it eects cellular transformation are still not clear. There are three basic criteria that Src must ful®ll in order to eect morphological transformation: (1) it must bind to the cell membrane via an amino terminal SH4 domain, (2) the kinase activity must be elevated and (3) Src must have functional and intact SH3 and SH2 domains. Concomitant with activation and morphological transformation, Src will phosphorylate a subset of cellular proteins on tyrosine. Thus, it was hypothesized that in order for Src to transform cells, it must be able to reside on the cell membrane, phosphorylate substrates and be capable of forming protein ± protein interactions via the SH3 and SH2 domains. In order to address the mechanism of transformation by Src, Kanner et al. (1990) hypothesized that one or more of the tyrosine phosphorylated cellular substrates in a Src-transformed cell likely played a critical role in modulating the transforming eects of Src. Several substrates were subsequently identi®ed. Antibodies generated against these substrates permitted the isolation of cDNA from phage display libraries. The cDNA inserts were subcloned and sequenced, identifying the Src substrates pp210 tensin (Davis et al., 1991) , pp125FAK , pp85 cortactin (Wu et al., 1991) , pp130cas (Harte et al., 1996) , pp120ctn (Reynolds et al., 1994) , p167 (Scholler and Kanner, 1997) and AFAP-110 (Flynn et al., 1993) .
AFAP-110 (originally called pp110) was of signi®-cant interest because it formed a stable complex with activated forms of Src, such as vSrc or Src 527F and could be detected as a co-immunoprecipitating protein with anti-phosphotyrosine antibodies via Western blot analysis (Reynolds et al., 1989a) . These early studies also demonstrated that the generation of three amino acid deletions within the SH2 or SH3 domains abrogated the transformation potential of Src 527F and prevented this 110 kDa tyrosine phosphorylated protein from co-immunoprecipitating with these Src 527F mutants. These data indicated that this protein had the potential to be both an SH2 and SH3 binding partner for Src. To con®rm this observation, the monoclonal antibody (mAb) 4C3 was generated by Kanner et al. (1990) , shown to be speci®c for the avian homolog of AFAP-110 (Kanner et al., 1990; Qian et al., 1999) , and used to demonstrate that this 110 kDa protein was a tyrosine phosphorylated substrate of Src which formed a stable complex with activated forms of Src. Using mAb 4C3, it was also demonstrated that AFAP-110 failed to bind to SH2 or SH3 deletion variants of Src ) still retained an ability to phosphorylate AFAP-110 on tyrosine. These data indicated that perhaps SH3 interactions were important for presenting AFAP-110 for phosphorylation and that both SH2 and SH3 binding were important for forging stable complex formation with Src.
MAb 4C3 revealed that AFAP-110 was co-associated with stress ®laments and the cell membrane in normal CEF cells . In Srctransformed CEF cells, where the disruption of actin ®lament integrity is a hallmark for transformation (Felice et al., 1990; Reynolds et al., 1989a) and ®laments are repositioned into`rosette-like' structures, AFAP-110 maintains co-localization with these actin ®lament rosettes. These data indicated that perhaps AFAP-110 functioned by facilitating interactions between Src and actin ®laments (Pawson, 1995) . Previous data predicted that transformation-competent forms of Src fractionated with the detergent-resistant cytoskeletal fraction, indicating that activated Src is closely associated with actin ®laments (Fukui et al., 1991) . Thus, AFAP-110 is positioned to facilitate this interaction and perhaps Src/AFAP-110 interactions may be important for aecting actin ®lament integrity in Src-transformed cells. Flynn et al. (1993) ®rst cloned the avian isoform of AFAP-110 and reported its sequence (GenBank accession #L20303). Later, a neural-speci®c isoform of AFAP-110, called AFAP-120, was reported to contain additional coding sequence near the carboxy terminus (Flynn et al., 1995) (GenBank accession #L20302). More recently, the sequence of the human isoform was reported (Bai et al., in preparation) (GenBank accession #AF188700). Other groups have also deposited partial sequences representative of AFAP-110 (GenBank accession #'s BB218408 and BB021778). Evidence supplied by Bai et al. as well as sequences deposited by the human genome project (http://www.ncbi.nlm.nih.gov) indicate that the gene for AFAP-110 is present on the distal part of the short arm of chromosome 4, at site 4p16.1 (also, see the human genome maps provided in Nature, volume 409, 2001, chromosome 4 map).
The predicted coding sequence of AFAP-110 indicates that it has a very high homology between chicken and human (87%, Bai et al., submitted). A functional domain structure can be predicted partly from the sequences and partly from experimental data (Figure 1) . Here, AFAP-110 is predicted to contain a carboxy terminal actin-binding domain (Qian et al., 2000) with several amino terminal protein-binding motifs, including an SH3 binding motif (Guappone and Flynn, 1997) , two SH2 binding motifs , two pleckstrin homology domains (Gibson et al., 1994; Shaw, 1996) , a leucine zipper motif (Qian et al., 1998) and a strong target sequence for ser/thr phosphorylation (Flynn et al., 1993) . The amino terminus also contains several other hypothetical binding sites that predict interactions with a variety of signaling proteins and/or lipids. A representation of the domain structure of AFAP-110 is included in Figure 1 . These data indicate that AFAP-110 functions as an adaptor protein, which could link a variety of signaling proteins to actin ®laments. Interestingly, AFAP-110 also has an intrinsic capability to alter actin ®laments in response to phosphorylation or deletional/site-directed mutagenesis. Herein, we will review how AFAP-110 interacts with actin ®laments, known and hypothetical binding partners and how AFAP-110 is able to aect actin ®lament integrity.
AFAP-110 has the capacity to multimerize AFAP-110 contains a carboxy terminal leucine zipper motif that lies just amino terminal to the actin binding domain (Qian et al., 1998) . Leucine zipper motifs are ahelical structures that contain a heptad repeat of leucine residues (Kouzarides and Zi, 1988) . Although commonly associated with transcription factors, leucine zipper motifs are also detected in a variety of actinassociated proteins, such as Cupidin, wish and dystrophins (Fukuoka et al., 2001; Morris et al., 1998; Shiraishi et al., 1999) . In these proteins, leucine zippers serve to form complexes between the cytoskeleton, the zipper containing protein, and other binding partners. Leucine zipper motifs typically forge homodimeric or heterodimeric interactions with other leucine zipper motifs, which are stabilized by hydrophobic interactions and limited in speci®city by charged residues (Hodges, 1996) . Leucine zipper motifs will also modulate protein interactions by binding to opposing sites that are not, themselves, a leucine zipper. For example, the HSP90 protein will dimerize via its leucine zipper motif; however, the opposing binding site resides among amino terminal residues that are not themselves a leucine zipper motif (Nemoto et al., 1995) .
The leucine zipper motif of AFAP-110 was hypothesized to facilitate self-association of AFAP-110 (Qian et al., 1998) . To test this, Qian et al. (1998) generated GST-encoded fusion proteins, which expressed the carboxy-terminal sequences encoded by amino acids 511 ± 637, (GST-cterm) that included the leucine zipper motif and surrounding sequences. GST-cterm was able to anity absorb cellular AFAP-110. Deletion of the leucine zipper motif from GST-cterm abrogated its ability to anity absorb cellular AFAP-110, indicating that AFAP-110 had the capacity to self-associate via the leucine zipper motif. Interestingly, the GST-cterm fusion proteins failed to anity absorb cellular AFAP-110 when it was co-expressed with Src 527F . These data indicated that signaling from Src 527F may aect the conformation of cellular AFAP-110 which could also eect its self-association. Here, a conformational change is de®ned by loss of access for the leucine zipper motif to its opposing binding site within cellular AFAP-110. Thus, changes in conformation were predicted to have occurred in response to Src 527F that aected multimerization of AFAP-110. This hypothesis was veri®ed using gel ®ltration analysis, whereby cellular AFAP-110 fractionated in at least three separate peaks, representing multimers (such as tetramers and trimers), as well as a population of monomers. However, co-expression of Src 527F caused AFAP-110 to fractionate in a single peak that also contained bound Src 527F (Qian et al., 1998) . Based on the molecular weight of the AFAP-110/Src 527F complexes within this single peak, it was predicted that AFAP-110 would exist as either a dimer or a trimer, bound to two or one Src 527F molecule(s), respectively. The signals generated by Src 527F likely aected the way in which the leucine zipper motif facilitates intramolecular interactions between AFAP-110 molecules for the purposes of multimerizing, as deletion of the leucine zipper motif causes AFAP Dlzip to exist only in a single peak that predicts a dimer (Qian and Flynn, unpublished data) . These data demonstrated that AFAP-110 existed within cell lysates as a multimer and that signals emanating from Src 527F could alter the conformation and reduce the multimeric status of AFAP-110. Because AFAP-110 can bind to actin ®laments directly and can multimerize, then it was likely that AFAP-110 also could function as an actin ®lament cross-linking protein. Furthermore, cellular signals that would reduce self-associations may also alter the actin ®lament cross-linking properties of AFAP-110.
AFAP-110 binds to actin ®laments and facilitates ®lament cross-linking
To establish AFAP-110 as a potential modulator of actin ®lament structures, Qian et al. (2000) investigated the potential for AFAP-110 to interact with actin. A direct interaction between AFAP-110 and F-actin was noted in co-pelleting assays and supported by the characterization of two actin binding domains near the carboxy-terminus of the protein (Qian et al., 2000) . Deletion of these domains abrogated the colocalization of AFAP-110 with actin ®laments, while expression of this carboxy-terminal region alone resulted in the colocalization with actin ®laments. Thus, this actinbinding region is both necessary and sucient for actin ®lament binding in vivo. AFAP-110 also has the capability to self-associate, indicating that it may have an ability to cross-link actin ®laments. In eukaryotic cells, the majority of actin ®laments (F-actin) are crosslinked into two main structure types by actin-binding proteins in vivo: these are the meshwork (isotropic network) and the bundle (Matsudaira, 1991; Wachsstock et al., 1993) . The actin bundle contains individual actin ®laments tightly packed to form parallel arrays with identical polarity. These structures are detected in membrane projections, actin ®laments and muscle sarcomeres. Conversely, the actin meshwork is a structure of individual actin ®laments that form a loosely grouped, orthogonally-oriented network seen in the cell body and cell cortex (Matsudaira, 1991) . This structure is stabilized by the presence of actin crosslinking proteins at the intersections of individual ®laments. The formation of actin ®laments into bundles or network structures is dependent upon the properties of actin ®lament cross-linking proteins. Actin cross-linking proteins usually have at least two actin-binding domains or dimerize if they contain only one actin-binding domain per monomer. Larger, longer and relatively¯exible actin cross-linking proteins tend to cross-link actin ®laments into networks while smaller, shorter and rigid actin cross-linking proteins usually bundle actin ®laments into parallel arrays (Fechheimer and Zigmond, 1993; Matsudaira, 1991; Pollard and Cooper, 1986) . Low speed co-sedimentation assays can be used to demonstrate the capability for an actin ®lament binding protein to cross-link actin ®laments. Here, at 20 800 g, actin ®laments fail to pellet unless cross-linked. Qian et al. (submitted) demonstrated that actin ®laments were pelleted when they were incubated with rAFAP-110. However, rAFAP Dcterm , which lacks the actin ®lament binding domain, was unable to pellet actin ®laments, indicating that AFAP-110 has the capability to cross-link actin ®laments which is mediated through the carboxy terminal region. Immuno¯uorescence and electron microscopic analyses of in vitro polymerized F-actin con®rmed the results of low sedimentary assay and demonstrated that AFAP-110 formed large aggregates to decorate and cross-link actin ®laments (Qian et al., submitted) .
The capability of AFAP-110 to cross-link actin ®laments was dose-dependent. Low concentrations of AFAP-110 loosely cross-linked actin ®laments upon co-sedimentation and failed to induce visible actin bundles upon microscopic analysis. High concentrations of AFAP-110 tightly cross-linked actin ®laments and partially aggregated them into large, branched structures. The results resemble the eects of a-actinin upon actin ®laments, whereby a-actinin loosely networks actin ®laments at low concentrations and tightly bundles actin ®laments at higher concentrations, although the appearance of cross-linked actin ®laments was somewhat dierent between AFAP-110 and aactinin. These results are consistent with the stoichiometry of actin cross-linking proteins bundling actin ®laments. The optimal stoichiometry in actin bundles is larger than one actin cross-linking protein per 20 actin subunits while this ratio in actin networks is much lower. An increase in this ratio of actin cross-linking proteins to actin subunits would promote the transition of actin ®laments from networks to bundles, as shown with a-actinin (Matsudaira, 1991; Wachsstock et al., 1993; Xu et al., 1998) . As AFAP-110 demonstrates this type of cross-linking activity, it was concluded that AFAP-110 may play a role in the dynamic transitions of actin bundling necessary for the continual rearrangement of the actin cytoskeleton.
Microscopic analysis of AFAP-110 in cells supports this hypothesis. AFAP-110 localizes with stress ®bers in quiescent cells, and is concentrated in cell motility structures such as lamellipodia, ®lopodia and membrane rues upon their induction (Qian et al., 1998; Qian et al., 2000) . Each of these cellular structures contains tightly bundled actin ®laments (Cramer, 1997; Matsudaira, 1991) . Lamellipodia and membrane rues also contain nascent actin ®laments that are in dynamic interconversion between bundles and networks (Oldenbourg et al., 2000; Small, 1994; Verkhusha et al., 1999) . Thus AFAP-110 may play a role in actin ®lament crosslinking in various actin structures.
It is possible that large amounts of AFAP-110 might be recruited to these regions through cooperative binding. In a study by Qian et al. (submitted) the association of rAFAP-110 with actin ®laments appeared to occur through a lateral association, based on biochemical and electron microscopic analyses. In addition, AFAP-110 appeared to demonstrate cooperativity in binding, with a Hill coecient of 3.2, indicating that the association of AFAP-110 with actin ®laments promotes the association of additional AFAP-110 molecules with actin ®laments. Furthermore, using Triton X-100 solubilized cell lysates, it was demonstrated that more than 50% of the AFAP-110 is in the insoluble fraction ( Figure 2 ) indicating that the majority of cellular AFAP-110 would be tightly associated with actin ®laments. Thus, some free or soluble AFAP-110 may be available for recruitment to actin ®laments. Neither expression of Src 527F nor cSrc exert a large change in the distribution of AFAP-110 among cytoskeletal and cytoplasmic cellular fractions. Interestingly, immunoprecipitation of AFAP-110 from the Triton X-100 soluble and insoluble fractions followed by anti-phosphotyrosine blotting demonstrate that all the tyrosine phosphorylated AFAP-110 exists within the insoluble fraction, indicating that AFAP-110 may be a substrate for Src 527F when it is tightly associated with actin ®laments (Flynn, unpublished data) . This phosphorylation state of AFAP-110 is also in complex with Src via SH2 interactions. These data indicate that when AFAP-110 is recruited to actin ®laments, it may also foster recruitment of soluble AFAP-110 proteins to actin ®laments in a cooperative fashion. This in turn could aect actin ®lament crosslinking and facilitate the creation of larger signaling complexes.
Modular domains in AFAP-110 -SH3 interactions with AFAP-110
AFAP-110 contains two adjacent proline-rich motifs that resemble a consensus SH3-binding motif (Guappone and Flynn, 1997) , according to previous predictions (Ren et al., 1993; Weng et al., 1995) ) had no eect on anity absorption (Guappone and Flynn, 1997) . These data, as well as additional site-directed mutagenesis studies, indicated that the amino-terminal, proline-rich SH3 binding motif was responsible for contacting the Src SH3 domain. Co-expression studies demonstrated that the AFAP 71A mutant failed to form a stable complex with Src 527F indicating a role for SH3 interactions in mediating stable complex formation. In addition, anity absorption experiments using the Lyn or Fyn SH3 domains (GST-SH3 lyn and GST-SH3 fyn ) demonstrated that these fusion proteins could also anity absorb AFAP-110; however, the cYes SH3 domain (GST-SH3 yes ) was unable to absorb cellular AFAP-110 (Flynn et al., 1993; Guappone and Flynn, 1997; Summy et al., 2000) . These data indicate a mechanism for generating speci®city in signaling among Src family kinases via SH3 interactions. Further experiments examined this hypothesis by predicting that activated cYes would also fail to interact with AFAP-110. Interestingly, it had been previously demonstrated that vYes failed to form a stable complex with AFAP-110 and was de®cient for phosphorylation of AFAP-110 (Kanner et al., 1990) . Chimeric constructs of Src 527F / cYes in which the Src 527F kinase domain was fused to the SH4-Unique-SH3-SH2 domains of cYes were unable to form a stable complex with AFAP-110. Signi®cantly, chimeric constructs in which only the Figure 2 AFAP-110 is found in both the Triton-soluble and -insoluble fractions. Cos-1 over-expressors were separated into triton-soluble and -insoluble fractions after 3 min or 10 min to determine resistance to extraction. Cells expressing AFAP-110 and Src 527F , AFAP-110 and cSrc, of AFAP-110 alone showed a signi®cant portion of AFAP-110 in the triton-soluble fraction after 3 min which was increased after 10 min of triton extraction. Fractions are labeled as: T-total lysate, S-Triton-soluble and I-Triton-insoluble SH3 domain of cYes was substituted into Src 527F failed to form a stable complex with AFAP-110 as well (Summy et al., 2000) . These data indicate that SH3 interactions are required for stable complex formation with AFAP-110 and that speci®city in signaling between cSrc and cYes might be achieved partly through dierential SH3 binding partners.
SH2 interactions and tyrosine phosphorylation of AFAP-110
AFAP-110 is a tyrosine phosphorylated substrate for Src 527F in vitro and in vivo (Flynn et al., 1992 (Flynn et al., , 1993 . AFAP-110 contains six potential SH2 binding motifs as described by . Using site-directed mutagenesis, the individual tyrosine residues were mutated independently or in tandem to Phe and ®ve sites for tyrosine phosphorylation were identi®ed as being potential Fincham et al. (2000) in which phosphatidylinositol 3-kinase (PI 3-kinase) can either facilitate, or is associated with, the transport of Src 527F into focal adhesion structures. Lastly, it is possible that the multiple sites of tyrosine phosphorylation may also assist in bringing activated Src in proximity to other SH2 domain containing proteins.
It is noteworthy that co-expression of null SH2 or SH3 binding partners of AFAP-110 with Src 527F does not block the transformed phenotype induced by Src 527F (Guappone-Koay and Flynn, unpublished data PH domain-directed interactions between AFAP-110 and signaling molecules
Pleckstrin homology domains comprise a family of modular domains of around 100 residues found in a variety of proteins that have been shown to facilitate molecular interactions with either proteins or phospholipids (Shaw, 1996) . PH domains, like most other modular binding domains, vary greatly from one protein to another, in respect to binding speci®city and primary sequence. The tertiary structure of PH domains, however, is relatively well conserved, as shown in Figure 3 . The diversity of primary sequence appears to lend to the ability to bind other molecules with variable anities, when comparing dierent PH domains. For example, phospholipid binding anities vary greatly between individual PH domains with the PH domain from PLC-d1 preferring Ins-(1,4,5)P3 and PtdIns(4,5)P2, while others, like the PH domains from Btk and PKB, prefer PtdIns(3,4,5)P3 (Gray et al., 1999; Kojima et al., 1997; Lemmon et al., 1995) . Similar disparities for protein binding are seen for protein binding partners for PH domains (Rodriguez et al., 1999) . Among the proteins which have been shown to bind PH domains are serine/threonine kinases like PKC, WD40-repeat containing proteins RACK1, Gbg, and others. The large, globular structure of the PH domain may permit the concomitant binding of several of these binding partners as well. This has been demonstrated for the WD40-repeat containing proteins (whose binding relies heavily on the alpha-helix of the PH domain) and PKC, which binds to an opposite face of the PH domain involving the 2nd ± 4th beta strands. Thus the role of PH domains may be to approximate binding partners for the formation of signaling complexes.
The amino-terminal PH domain of AFAP-110 directs interactions with PKC AFAP-110 contains two potential PH domains which ank a stretch with several putative sites for serine/ threonine phosphorylation. Attempts have been made at examining potential binding partners for these PH domains. Data by Baisden et al. (submitted) have shown that the amino-terminal PH domain of AFAP-110 can direct interactions between this protein and speci®c PKC isoforms, including members of the classical family of PKCs and the novel PKCl/i. The carboxy-terminal PH domain failed to show similar interactions, but was noted to anity absorb a kinase activity which phosphorylated a known PKA substrate. Sequence comparisons of these PH domains shows that the amino-terminal PH domain shares highest homology with PH domains from b-spectrin and Dynamin, which are also thought to direct interactions with PKCs, while the carboxy-terminal PH domain shares highest homology with the Btk PH domain. The amino-terminal PH domain also shares homology with the PH domain from Btk, which has been extensively investigated for its ability to interact with PKC. A modeling of the structure of this PH domain of AFAP-110 was constructed, based on the structure of the b-spectrin PH domain, as solved by NMR (Macias et al., 1994) . This structure and the sequence homology it was based upon were used to determine the residues of the PH domain of AFAP-110 which likely correspond to the speci®c structural elements conserved in PH domains. Table 1 shows that the regions of homology between the aminoterminal PH domain of AFAP-110 and the PH domains of b-spectrin, Dynamin and Btk are highest for the ®rst beta sheet, which includes strands 1 ± 4. This sheet forms one side of the structure and provides a continuous face which likely binds to PKC. The sequences of Spectrin, Dynamin, and Btk are shown in this table, as these domains have been well studied for their ability to bind both PKC and phosphoinositides. The consensus PKC binding sequence presented, however, also considers several other PH domains which also bind PKC. The amino-terminal PH domain of AFAP-110 ®ts this consensus well, with seven out of eight residues matching. If we include the buried hydrophobic residues indicated in this table with *, this number is 14 out of 15. This table also considers the carboxyterminal PH domain of AFAP-110, which matches four out of eight non-buried residues, and 10 out of 15 total consensus residues. Experiments have shown this carboxy-terminal PH domain is de®cient for binding to PKC (Baisden et al., in preparation). A model of the amino-terminal PH domain of AFAP-110 and the potential binding sites for partners, including PKC, are shown in Figure 3 . This ®gure includes the PH domain of Spectrin for comparison (Hyvonen et al., 1995) . Additional evidence has been found that the amino-terminal PH domain of AFAP-110 directs interactions with PKC through this ®rst beta sheet, as a deletion of a portion from the 2nd to the 4th beta strands abrogates this interaction (Baisden et al, in preparation). Additionally, the speci®c deletion of a portion of the other beta sheet, from the 5th to the 7th beta strands, does not aect this interaction. Thus, it appears likely that interactions between PKC and AFAP-110 involve the aminoterminal PH domain. 
Additional potential binding partners for the PH domains of AFAP-110
In addition to binding PKC, the PH domains of Spectrin and Dynamin are known to bind both phospholipid second messengers and WD40 repeat containing proteins, such as RACK1 and Gbg (Rodriguez et al., 1999) . The potential for AFAP-110 to interact with phospholipids is demonstrated by sequence homology in Table 1 and described below. Likewise, the potential interactions between AFAP-110 and WD40 repeat containing proteins is also discussed below, including a homology comparison in Table 2 . These potential interactions are summarized in Table 3 , which additionally includes known and hypothetical binding partners for AFAP-110.
Potential interactions with phospholipids
In the case of phospholipid second messengers, the PH domains of b-spectrin and Dynamin bind to the inositol head group of phosphoinositides by virtue of several basic residues in the 1st, 2nd, and 3rd beta strands and may additionally include basic residues from the 5th beta strand (Lemmon and Ferguson, 2000) . Additionally, the highly conserved tryptophan forms a hydrogen bond with the 1-phosphate of Ins(3,4,5)P3 (Lemmon and Ferguson, 2000) . The exact positions of the basic residues (usually lysines) are quite variable, as is the preference for speci®c phosphoinositides. These two factors may be interdependent. In contrast, the overall site of this interaction may be similar in most of these domains, and appears to be on the face of the domain opposite from the alpha helix where the two beta sheets meet. Phosphoinositides with an attached diacylglycerol or other moiety (PtdIns(4,5)P2, PtdIns(3,4,5)P3, etc.) appear to be accommodated by the high exposure of the 1-phosphate to solvent, allowing this moiety to maintain its insertion in the hydrophobic membrane (Lemmon and Ferguson, 2000) . The amino-terminal PH domain of AFAP-110 contains several basic residues as well as a conserved tryptophan which appear to be positioned similarly to those residues known to coordinate binding of the inositol head group of phosphoinositides, as shown in Table 1 . A model of this PH b1 b2 b3 
Consensus sequence for this stretch is shown and symbols used are as follows: + indicates positively charged residues, 1 indicates aromatic residues, C indicates hydrophobic residues, * indicates buried hydrophobic residues which stabilize the PH domain, as determined by NMR. Consensus is modi®ed from Waldron et al., 1999 and Yao et al., 1997 . Residues contained within beta sheets are in bold, and sheets labeled as designated from the Btk structure. Residues which are thought to be involved in phospholipid binding are outlined. Sources are: (1) 
A consensus sequence for this stretch is shown and symbols used are as follows: C indicates hydrophobic residues, -indicates negatively charged residues, and * indicates buried hydrophobic residues which stabilize the PH domain, as determined by NMR. Consensus is modi®ed from Touhara et al. (1994) and identi®es positions common to ®ve or more of the sequences shown. Residues contained within beta sheets are in bold. Sequences and alignments are from Touhara et al. (1994) and NCBI structure database information Figure 3 , which also shows the structure of the PH domain from Spectrin in complex with Ins(3,4,5)P3. The basic residue side chains of Spectrin which interact with this phosphoinositide are shown in blue, as are the corresponding residues in the AFAP-110 PH domain. The carboxy-terminal PH domain of AFAP-110 also contains basic residues and the conserved tryptophan in the regions responsible for phosphoinositide binding, as shown in Table 1 , and may also interact with phosphoinositides. The potential for either PH domain to bind these signaling components remains untested. The function of phosphoinositide binding by PH domains appears to be the localization of the protein at the cell membrane. Some PH domains, as mentioned previously, bind preferentially to constitutive components of membranes (Ins(3,4,5)P3), while others preferentially bind inducible products of signaling pathways (PtdIns(3,4,5)P3) and may allow signal dependent localization to membranes. The speci®city of either PH domain of AFAP-110 for phosphoinositides may provide clues as to whether either domain directs AFAP-110 to the cell membrane.
Potential interactions with WD40 repeat containing proteins
The binding of PH domains to WD40 repeat containing proteins is thought to involve the carboxy-terminal alpha helix and surrounding regions. This has been demonstrated for several proteins, including b-spectrin, Dynamin, and others (Touhara et al., 1994) . Table 2 attempts to create a consensus sequence for the binding of these PH domains to WD40 repeats. This consensus is included and indicates the binding of PH domains to WD40 repeats may involve some conserved, charged residues. Analysis of the alignments of the PH domains of AFAP-110 shown in this Figure indicates that both PH domains of AFAP-110 ®t this consensus, matching seven out of nine consensus charged and hydrophobic residues. Thus, either PH domain has the potential for binding WD40 repeat containing proteins. The consensus binding sequences shown here were based, in part, on those reported previously, as noted in the Figure legends . It is the authors' opinion that much of the homology seen between these sequences represents conserved hydrophobic residues which are largely involved in stabilizing the tertiary structure of the PH domain, rather than interacting with binding partners. This is based mostly upon the observation that the side-chains of these hydrophobic residues are buried within the structure and not exposed or available for interaction with other partners. These observations were noted upon inspection of the solution structures of the PH domains included in Table 2 . Thus, the consensus sequences created for both PKC and WD40 repeat binding focused on more exposed residues and should be read with this caveat in mind.
Additional hypothetical protein interactions with AFAP-110
Anity absorption experiments were used to demonstrate the feasibility of AFAP-110 forming stable complexes with known signaling proteins. As mentioned earlier, AFAP-110 can be anity absorbed by GST-fusion proteins encoding the Lyn and Fyn SH3 domains. In addition, GST-SH2 fusion proteins representing Lyn, Fyn and even cYes are also able to anity absorb AFAP-110 (Flynn et al., 1993; Guappone et al., 1998; Guappone and Flynn, 1997; Summy et al., 2000) . Because AFAP-110 is not an SH3 binding partner for cYes, and these interactions are important for working in concert with SH2 binding to facilitate stable complex formation with Src, then it was hypothesized that cYes would not be a binding partner for AFAP-110. However, it is possible that either Fyn or Lyn may interact with AFAP-110. Lyn is found predominantly in B cells, while cFyn is found in platelets and neurons. We have detected signi®cant levels of AFAP-110 in DT10 avian B cells, and AFAP-110 is expressed at very high levels in neurons (Flynn et al., 1995) . Thus, it is possible that either cFyn or cLyn (or possibly other Src family members) may bind to and signal through AFAP-110.
AFAP-110 also contains a proline-rich motif between amino acids 75 ± 84, which is adjacent to the Src SH3 binding motif (amino acids 62 ± 71). This motif resembles a WW domain binding motif. It is possible that some WW domains may be able to forge an interaction with AFAP-110 but currently there is no data to support this. Also of interest is the neuronal form of AFAP-110, AFAP-120. This isoform contains an insert or additional exon that encodes 86 amino acids. Analysis of the genomic sequence of human AFAP-110 from the human genome project demonstrates that homologous coding sequence for the NINS can be identi®ed between the coding sequence that de®nes the surrounding exons, indicating that the NINS in fact does arise as a result of alternative splicing (Flynn et al., unpublished data) . In chicken the NINS contains a proline-rich motif that was necessary for anity absorption of a 67 kDa protein, p67 (Flynn et al., 1995) . The p67 protein could be absorbed from non-neuronal tissues indicating that it may not be a speci®c binding partner for AFAP-120. Nevertheless, these data indicate that the proline-rich region within the NINS may be required for modulating additional protein interactions with AFAP-120.
AFAP-110 as a cSrc activator
Interestingly, deletion of the leucine zipper motif (AFAP Dlzip ) followed by expression of AFAP Dlzip in cells results in a phenotype that is not unlike that of Src 527F transformed cells (Qian et al., 1998) . Here, actin ®laments are repositioned into actin-rich rosettes and cell motility structures are detected.
AFAP-110 as an adaptor protein JM Baisden et al Thus, it was possible that AFAP Dlzip could alter actin ®lament organization either directly, via direct eects upon actin ®laments, or indirectly. One attractive hypothesis is that AFAP-110 may aect actin ®lament integrity indirectly, functioning as an upstream activator of cSrc. Crystallographic analysis of Src or Hck demonstrate that these related kinases exist in a closed conformation mediated by intramolecular interactions that function to repress kinase activity. Here, the SH2 domain of Src contacts the carboxy terminal phosphotyrosine at amino acid position 527 (Y 527 ), (Liu et al., 1993) . In addition, the SH3 domain contacts a type II left-handed polyproline helix that exists in the linker domain, between the SH2 and kinase domains (Williams et al., 1997) . Previous data demonstrated that deletions within the cSrc SH3 domain would activate cSrc's tyrosine kinase activity (Seidel-Dugan et al., 1992) , indicating that intramolecular interactions may be important for stabilizing the structure of this kinase in a repressed conformation. Two studies by Moare® et al. (1997) and Briggs et al. (1997) demonstrated that the HIV protein, Nef, is an SH3 binding partner for Hck and could activate Hck by virtue of its SH3 binding properties. Here, SH3 binding of Nef to Hck would displace intramolecular interactions and relax the repressed conformation of Hck, leading to activation of Hck tyrosine kinase activity (Briggs et al., 1997; Moare® et al., 1997) . Thus, these data demonstrated that SH3 binding partners could activate Src family kinases.
Recent data indicate that AFAP-110 may also have the potential to activate cSrc by a similar mechanism (Baisden et al., submitted) . Here, it was demonstrated that AFAP Dlzip was hyperphosphorylated on serine, threonine and tyrosine and that cellular tyrosine phosphorylation was increased relative to AFAP-110 transfected or untransfected cells. Antibodies that speci®cally immunoreact with the activated form of cSrc (anti-phospho-Y416, Upstate) also demonstrated increased immunoreactivity in AFAP Dlzip transfected cells, relative to control and wild-type AFAP-110 expression. Finally, transfection of a chimera of AFAP ) which is predicted to be unable to bind to the Src SH3 domain was unable to activate cSrc based on an inability to upregulate immunoreactivity with the phospho-Y416 antibodies or cellular tyrosine phosphorylation. These data indicate that mutants of AFAP-110 that alter actin ®lament integrity are also capable of activating Src family kinases. It is possible the dissolution of actin ®laments seen upon the activation of cSrc by AFAP-110 mutants may be accomplished via the documented stimulation of Rho GTPase activity by activated Src (Fincham et al., 1999) , based on the observation that dominantpositive Rho can block the eects of AFAP Dlzip upon actin ®laments. These data suggest that cellular signals which alter AFAP-110 conformation may enable it to activate cSrc and alter actin ®lament integrity.
Phosphorylation of AFAP-110 and its aect on function
As mentioned above, tyrosine phosphorylation of AFAP-110 by Src directs the formation of a stable complex between these molecules. Additionally, signals generated by Src 527F also alter the conformation of AFAP-110 and aect self-association. However, it appears that the mechanism by which Src 527F aects multimerization of AFAP-110 occurs independently of tyrosine phosphorylation. Baisden et al. (in preparation) demonstrated that the phosphorylation of AFAP-110 by PKC is responsible for the change in conformation and self-association in response to Src activation. This hyperphosphorylation and subsequent conformational change appear to be involved in the direct activation of cSrc by AFAP-110 as well as a change in the actin cross-linking activity of AFAP-110, as described below. Thus, the phosphorylation of AFAP-110 appears to play a key role in modulating its aects on the actin cytoskeleton via both direct and indirect mechanisms.
Deletion of the leucine zipper motif or PKC phosphorylation up-regulates AFAP-110's ability to cross-link actin ®laments AFAP-110 has an intrinsic, regulated ability to crosslink actin ®laments which is revealed by deletion of the leucine zipper motif (Qian et al., submitted) . Low concentrations of AFAP Dlzip cross-linked actin ®laments into large aggregates when observed under low speed cosedimentation assays, confocal immuno¯uorescence microscopy or electron microscopy. This corresponds with the change in the self-association of AFAP-110 from multimers to homodimers upon the deletion of the leucine zipper motif (Qian et al., 1998) . Under electron microscopy, the physical size of rAFAP dlzip complexes is noticeably smaller than that of rAFAP-110, which is consistent with the biochemical analysis of AFAP-110 self-associations. It is possible that deletion of the leucine zipper motif of AFAP-110 transitions AFAP-110 from a larger, loosely-de®ned actin ®lament cross-linking protein to a smaller, more ecient cross-linker, enabling it to tightly cross-link actin ®laments to large aggregates. PKC phosphorylation also up-regulated AFAP-110's ability to cross-link actin ®laments as PKC phosphorylated AFAP-110 cross-linked actin ®laments into larger aggregates containing bundled actin ®laments (Qian et al., submitted) . PKC-a can phosphorylate AFAP-110 both in vivo and in vitro (Qian et al., submitted) , and phosphorylation by PKC reduces the ability of AFAP-110 to multimerize in vitro (Baisden et al., in preparation), while in vivo PKCa phosphorylation positions AFAP-110 into cell motility structures (Baisden et al. unpublished observations) .
PKC phosphorylation induces the formation of lamellipodia and ®lopodia (Dwyer-Nield et al., 1996) , where the actin ®laments are cross-linked into either network or bundles while reducing stress ®lament structures (Cramer, 1997; Oldenbourg et al., 2000; Verkhusha et al., 1999) . A paradox of these results is that most of the known actin ®lament cross-linking proteins are negatively regulated by PKC phosphorylation which dramatically decreases the abilities of Fascin, MARCKS and VASP to cross-link actin ®laments (Bubb et al., 1999; Harbeck et al., 2000; Hartwig et al., 1992; Huang et al., 1997; Ishikawa et al., 1998; Yamakita et al., 1996) . Src phosphorylation similarly inhibits the ability of cortactin to cross-link actin ®laments (Huang et al., 1997) . AFAP-110 may upregulate actin ®lament cross-linking, mediating the eects of PKC phosphorylation on actin ®laments within cell motility structures. PKCa activation directs a loss of stress ®laments; however, it also directs an increase in cell motility. As motility structures recruit newly forming actin ®laments and there is strong evidence for actin ®lament bundling and cross-linking within these structures, it is possible that AFAP-110 may mediate the actin ®lament cross-linking within these structures. Additional evidence supports the potential requirement for AFAP-110 in the formation of actin-based motility structures, as mutants of AFAP-110 that block the phosphorylation of AFAP-110 by PKCa also are able to block the aects of PKCa upon actin ®laments (Baisden et al., in preparation) . This work explores the potential for PKC to activate cSrc, as mentioned above. The mechanism proposed involves the direct activation of cSrc by AFAP-110 through SH3 interactions in response to a PKC phosphorylation-induced conformational change. Thus, AFAP-110 may mediate the eects of PKCa upon actin ®laments in two ways: First, PKCa binding may permit phosphorylation of AFAP-110 and a conformational change that enables AFAP-110 to become a more ecient SH3 binding partner and activate cSrc signaling pathways that direct changes in actin ®lament integrity. Consistent with this, AFAP 71A prevents PKCa from activating cSrc, indicating that AFAP-110 mediates PKC activation of cSrc in an SH3 dependent fashion. In addition, PKCa phosphorylation of AFAP-110 would reduce selfassociation and enable AFAP-110 to cross-link actin ®laments within lamellipodia and ®lopodia more eciently, which may assist in the formation of these motility structures.
Physiological functions for AFAP-110
Western blot analysis of tissue culture cell lines demonstrated that AFAP-110 could be detected in almost every cell line examined, including ®broblast, epithelial and endothelial cell lines as well as cells of hematopoietic lineage (Flynn et al., 1995) . Expression patterns in cells are mainly limited to stress ®laments and the cell membrane, although some peri-nuclear localization has been observed (Flynn et al., 1993) . In tissues, AFAP-110 was expressed in a variety of tissues tested such as kidney, liver, or lung, but was detected at highest levels in brain and muscle tissue, including heart, skeletal muscle and intestine (smooth muscle). AFAP-110 was also detected in myoepithelium cells in breast tissue as shown in Figure 4 , indicating a strong representation in the basic types of muscle tissues.
AFAP-110 is detected at very high levels in the developing avian and mouse brain (Flynn et al., 1995) . Immunohistochemical analysis demonstrated that AFAP-110 was detected in the Purkinje cell layer of the cerebellum in the adult rat brain (Clump et al., in preparation); however, expression was strongest in the olfactory bulb (OB) as shown in Figure 5 . Expression patterns of AFAP-110 were strongest in what appeared to be neural ®bers and were not easily detected in the cell bodies. AFAP-110 expression was limited to the primary order neurons that traverse from the nose to glomeruli, where these neurons terminate with second order neural cells. Olfactory neurons of this type are unique in that they must regenerate every 40 days (Murray and Calof, 1999) . The new olfactory neurons mature from stem cells and the nerve termini must migrate and synapse with second order neurons in speci®c glomeruli. Although the signi®cance of this Figure 5 Parasagittal section of rat brain immunoreacted with antiserum to AFAP. Dense AFAP expression is limited to the olfactory bulb (arrows). Lower levels of expression are found in hippocampus (*), septal (sn) and pontine nuclei (pn) and cerebellar cortex (cblm). D, dorsal; R, rostral expression pattern is not quite clear, it is noteworthy that Fyn knockout mice demonstrate signi®cant changes in glomerular structure and migration of olfactory neurons into the olfactory bulb (Yagi et al., 1993) . As AFAP-110 could be a potential binding partner for Fyn and AFAP-110 has an intrinsic capability to alter actin ®lament integrity, it is possible that AFAP-110 may play a role in modulating signals downstream of Fyn which govern migration of olfactory nerve termini to speci®c glomeruli. This hypothesis waits to be tested but it also oers a unique opportunity to generate a tissue-speci®c conditional knockout of AFAP-110 that would be predicted to survive to birth and may yield important clues for the physiological function of AFAP-110 and AFAP-120.
Interestingly, in rat lung, AFAP-110 is phosphorylated on tyrosine in response to mechanical stretch of rat embryo lung cells and cSrc becomes activated and forms a stable complex with AFAP-110 (Liu et al., 1996) . Mechanical stretch is simulated in an in vitro system whereby lung cells are plated in a spongy environment and the sponge can be torsionally stretched, causing the cells to stretch. These deformations in cellular structure are thought to resemble the changes in cell structure associated with inhalation/ exhalation. When cells change shape in this manner, actin ®laments must undergo rapid and coordinated changes to accommodate cell stretching. The fact that this mechanical stretch on cells activates cSrc signaling pathways indicates a mechanism for cellular signals to sense these changes and eect changes in actin ®lament integrity. As AFAP-110 is capable of activating cSrc, it is possible that AFAP-110 also participates in modulating these changes. It is noteworthy that in lung transplant tissues, AFAP-110 levels of expression are very low and cSrc is not activated in these cells, indicating a relationship between AFAP-110 expression levels and cSrc activity (Keshavjee et al., 2000) .
Future prospects for AFAP-110
AFAP-110 has an intrinsic capability to alter actin ®lament integrity in two ways: (1) it can activate cSrc dependent signaling pathways that alter actin ®lament integrity and (2) phosphorylation of AFAP-110 by PKC will increase its ability to cross-link actin ®laments. It is noteworthy that AFAP-110 undergoes a conformational change in transformed cells that correlates with changes in actin ®lament integrity and the formation of motility structures. This change in conformation appears to occur independently of tyrosine phosphorylation and correlates with an intrinsic capability to activate cSrc and alter actin ®lament integrity. Thus, it is possible that speci®c cellular signals that alter AFAP-110 conformation enable it to activate cSrc in an SH3-dependent fashion. The adaptor nature of AFAP-110 indicates it may ful®ll this function in response to signals from any of its known or potential binding partners, which may include Src, PI-3K, PKC, RACK1, Gbg, 14-3-3 proteins, and phospholipids. It will be important to identify these cellular signals. It is possible that cSrc activator proteins may play an important role in the etiology of some human cancers. It has been established that cSrc is activated in a number of human cancers including colon cancer, breast cancer, prostate cancer, neuroblastoma, Ewing sarcoma and rhabdomyosarcoma (Cartwright et al., 1990; Rosen et al., 1986) . However, the evidence for mutation of cSrc in human cancers is very slim (Reynolds et al., 1989b) , indicating that activation may involve cSrc-binding partners, such as AFAP-110. Thus, oncogene-activating proteins such as AFAP-110 may represent important targets for cancer intervention.
Physiologically, it will be important to establish a role for AFAP-110 in development and normal organ function in order to elucidate its normal function. It is noteworthy that AFAP-110 expression levels are highest in organs where changes in actin ®lament integrity are important to organ function, such as muscle or lung. The ability of AFAP-110 to alter actin structures in response to cellular signals indicates the potential for it to ®ll this role as required for the normal function of cells in these organs. In the brain, AFAP-110 is expressed at highest levels, and as an alternative splice form, in neurons. Given the constitutively high expression levels in the neurons of the olfactory bulb, which actively regenerate and path®nd to speci®c glomeruli, it is possible that cellular signaling pathways could utilize AFAP-110 to remodel actin ®laments for dierentiation and neuronal path®nding.
